Carotid atherosclerotic disease increases the risk for ischemic stroke and transient ischemic attack and challenges are presented when seeking the appropriate strategy of management. In this review, we will discuss the current diagnostic and treatment approaches of asymptomatic and symptomatic carotid stenosis (SCS). The definition of carotid plaques, staging of stenotic severity, and noninvasive tests including carotid duplex ultrasound, computed tomographic angiography, magnetic resonance angiography, and transcranial Doppler will be summarized. Optimal management for asymptomatic and SCS with medical therapy, carotid artery stenting, or carotid endarterectomy has been controversial and should be judged in specific clinical settings. More clinical data are needed to better understand the correlation of different diagnostic measures and the disease progress and to optimize the treatment approach to improve patient outcomes. 
introduction
Carotid atherosclerotic disease (CAD) refers to stenosis and occlusion of the carotid artery caused by atherosclerosis, where the carotid bifurcation and the proximal internal carotid artery (ICA) are most frequently affected. Progression of atheromatous plaques results in luminal narrowing and is often accompanied by plaque ulceration. Atherosclerosis progresses silently and the first symptom may be a stroke or transient ischemic attack (TIA), potentially devastating for patients. Overall prevalence of CAD differs from various studies. Data published from the Cardiovascular Health Study in 1998 suggested an overall prevalence of severe asymptomatic carotid stenosis (ACS) of 0.5%, [1] whereas data published in 1992 showed that was 1.07% for women and 1.22% for men. [2] A meta-analysis published in 2012 [3] estimated the general prevalence of severe ACS between 0% and 3.1%. The prevalence of moderate ACS was 0.2% and 0% in males and females younger than 50 years of age, respectively, and 7.5% and 5.0% in males and females older than 80 years of age, respectively. In addition, racial differences are suggested by data from lifeline screening [4] as there is a higher prevalence of clinically significant carotid stenosis in Native Americans and Caucasians than African Americans and Asians.
Based on the presence of symptoms, CAD can be divided into ACS and symptomatic carotid stenosis (SCS). ACS refers to CAD without a history of recent ipsilateral carotid territory ischemic stroke or TIA, while SCS refers to CAD with recent occurrence of focal neurologic symptoms including TIAs or nondisabling ischemic strokes characterized by ipsilateral carotid artery dominating region. [5] Only symptoms occurring within the previous 6 months caused by carotid stenosis should be taken into consideration.
Risk factors for CAD are essentially the same as those for traditional coronary artery disease and the United States Preventive Services Task Force has made recommendations for special screening of diseases of hypertension, diabetes mellitus, dyslipidemia, and unhealthy lifestyle habits such as smoking, imbalanced diet, or inadequate exercise. [6] Chronic hemodialysis program is another adverse factor as people with chronic kidney disease suffer a 5-10-fold higher risk of CAD than the general population.
In this review, we will briefly summarize the current techniques for diagnosing and evaluating CAD as well as up-to-date treatment of asymptomatic and SCS.
dEfinition and Evaluation
For patients with or without symptoms, evaluating the severity of CAD is always necessary to guide the appropriate therapy. Evaluation of the risk of perioperative cerebral ischemic events is especially important in the management of severe carotid artery stenosis. [8] While traditional noninvasive methods are widely used, newer technologies are being tested, such as using optical coherence tomography to evaluate of the posterior part of the eye. [9] Carotid plaque Advanced atherosclerotic plaques contain a fibrous cap and a necrotic lipid-rich core, infiltrated with inflammatory cells, sometimes with calcification, locally reflecting the severity of atherosclerosis. Carotid plaque morphology is classified as "smooth," "irregular," or "ulcerated." [10] Patients with mild or moderate stable plaques may have no clinical symptoms and may never realize their existence; however, destabilization or rupture of plaques can lead to life-threatening events. [11] Carotid intima-media thickness (IMT) can increase significantly in patients with existing plaques [12] and was previously thought to reflect atherosclerotic burden, but large variations in histological measurements of IMT in late-stage atherosclerotic disease challenge the validity of this assumption. Recent observations based on donor aortas also showed that IMT may not gradually increase as atherosclerosis progresses, making the association between IMT and CAD less reliable. [13] The presence of carotid plaque was found to be a much stronger predictor of increased risk for coronary heart disease, [14] stroke, and cerebral infarction. [15] The European Mannheim consensus [16] and American Society of Echocardiography [17] define plaques as a focal wall thickening of >50% (or 0.5 mm) of the surrounding IMT, or an IMT of >1.5 mm. In the Chinese Guidance of Ultrasound Examination in Stroke, a plaque is defined as a focal structural protrusion into the vessel lumen with an IMT >1.5 mm and thickening of >50% (or 0.5 mm) of the surrounding IMT. [18] The latter definition could be regarded as an improved version of the former.
Vulnerable carotid plaques are prone to rupture and thus need close observation and enhanced treatment. Several factors play a role in the formation of vulnerable plaques including age-associated changes, [19] an increased hemoglobin A1c level, [20] a decreased galectin-3 intraplaque level, [21] and the occurrence of neovessels within the plaque. [22] Contrast-enhanced ultrasonography finds that ulcerated plaques are more accurate for detecting disruption of the fibrous cap and have a higher sensitivity (91.3%) compared to traditional ultrasonography. [23] A combination of quantitative change assessment by high-resolution magnetic resonance imaging and qualitative change assessment by GrayScale Median analysis could also be used as a novel tool for detecting vulnerable plaques. [24] Quantification of carotid plaques is an important step of subclinical atherosclerosis assessment, which still lacks consensus for staging carotid plaque severity. [25] 
Severity of stenosis
Grading of severity of carotid artery stenosis ranges from mild (<50% stenosis), moderate (50% to 69% stenosis), and severe (70% to 99% stenosis) to occlusion (100% stenosis). Traditional methods for quantitatively evaluating the severity of stenosis include the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method, the European Carotid Surgery Trial (ECST) method, and the common carotid (CC) method. The first step in all the above methods is to measure the residual lumen diameter (RLD) at the most stenotic portion of the vessel. The difference among these methods is that NASCET method compares RLD with the lumen diameter in the normal ICA distal to the stenosis, [26] the ECST method compares RLD with the estimated probable original diameter at the site of maximum stenosis [27] and the CC method compares RLD with the lumen diameter in the proximal CC artery. [28] Results of all three methods have a nearly linear relationship with each other and have similar prognostic values. [28] Conventional contrast angiography remains the gold standard to evaluate the severity of ICA stenosis. In current clinical practice, noninvasive tests such as carotid duplex ultrasound (CDUS), computed tomographic angiography (CTA), magnetic resonance angiography (MRA), and transcranial Doppler (TCD) are sometimes preferred for their convenience and safety.
Carotid duplex ultrasound
CDUS is a noninvasive, safe, and relatively inexpensive technique for evaluating CAD by using B-mode and Doppler sonography to detect atherosclerotic obstruction of the carotid arteries. [29] CDUS measures focal increase in blood flow velocity to gauge the severity of the stenosis based on peak systolic velocity (PSV) and end-diastolic velocity (EDV). EDV is independently associated with future cardiovascular events where increases predict recanalization and neurological improvement from reperfusion therapy. [30, 31] Under criteria outlined by the Standards for Reporting of Diagnostic Accuracy, CDUS showed a sensitivity of 98% (95% confidence interval [CI]: 97% to 100%) and a specificity of 88% (95% CI: 76% to 100%) in the identification of stenosis ≥50% with a PSV ≥130 cm/s as well as a sensitivity of 90% (95% CI: 84% to 94%) and a specificity of 94% (95% CI: 88% to 97%) in the identification of stenosis ≥70% with a PSV ≥200 cm/s. [32] A simplified grayscale/mosaic ultrasound protocol was recently proposed to exclude significant severity, resulting in sensitivity, specificity, and negative predictive values to be 90%, 97%, and 100%, respectively, for detection of stenosis >50% in the ICA. [33] A major limitation of CDUS is that the diagnostic accuracy relies heavily upon the experience and expertise of the ultrasound operators. In addition, different laboratories may use different measurement thresholds and the magnitude of the variation can have clinically importance. [32, 34] 
Computed tomographic angiography
CTA enables an anatomic depiction of the carotid artery lumen and measurement of RLD by three-dimensional reconstructions. CTA is a better option in situations where CDUS may fail such as the existence of severe calcification, inadequate neck length, or high bifurcation. [35] In the assessment of severe carotid artery stenosis, CTA correlates well with digital subtraction angiography (DSA), especially for detection of occlusions, with a high sensitivity and specificity of 97% and 99%, respectively. [36] Carotid CTA detects a complicated plaque reliably with the maximum soft plaque component thickness, with the rim sign of adventitial calcification with internal soft plaque highly predictive of carotid intraplaque hemorrhage. [37, 38] CTA also predicts the risk of in-stent restenosis with high volumes of plaque components of <0 Hounsfield units. [39] Moreover, semiautomatic and automatic atherosclerotic plaque measurements using CTA showed overall diagnostic accuracy; however, confirmation by experienced radiologists is still necessary. [40, 41] Although there are benefits in using CTA, it requires a contrast agent and thus brings a higher risk for contrast-induced nephropathy to patients with impaired renal function, particularly those with concomitant diabetes or congestive heart failure.
Magnetic resonance angiography
MRA is also an attractive noninvasive technique for the detection of stenosis and atherosclerosis. MRA was once thought to overestimate the degree and length of stenosis, [42] but later findings showed comparable accuracy between three-dimensional time-of-flight (TOF) MRA and DSA. [43] In a study published in 2001, MRA correctly identified 34 of 37 near-total occlusions and all total occlusions [44] which confirmed the reliability of MRA in depicting occlusive carotid lesions. TOF MRA alone is accurate enough for the identification of severe stenosis and occlusions with sensitivities and specificities of 91.2% and 88.3% for severe ICA stenosis, respectively, and 94.5% and 99.3% for occlusions, respectively. Contrast enhancement (CE) MRA performs slightly better than TOF MRA, with sensitivities and specificities of 94.6% and 91.9% for severe stenosis, respectively, and 99.4% and 99.6% for occlusions, respectively. [45] A meta-analysis also concluded that CE MRA was more sensitive and specific than Doppler ultrasound, MRA, and CTA for severe stenosis. [46] Compared with CDUS, MRA is less dependent on operators and produces an image of the artery of interest but cannot be performed when the patient is unable to lie supine for long periods of time or has claustrophobia, a pacemaker, or ferromagnetic implants. MRA is also expensive to perform and time-consuming, making it less practical.
Transcranial Doppler
TCD noninvasively examines the major intracerebral arteries and assess real-time cerebral blood flow with physiological-flow-related information. The American Academy of Neurology suggests that TCD is possibly useful in evaluating severe extracranial ICA stenosis or occlusion. [47] TCD can detect middle cerebral artery microemboli that arise from the heart or carotid artery in patients with severe carotid artery stenosis. [48] A meta-analysis found the posttest probabilities of a stroke after a positive and negative TCD were 7.1% (95% CI: 5% to 10.1%) and 1.2% (95% CI: 0.6%-2.5%), respectively. [49] Utilizing cerebrovascular reserve capacity (CVRC) measurements, a hemodynamic parameter obtained with TCD-inhalation CO 2 tests, TCD may further add value for evaluating the brain's tolerance of ischemia with high availability and low cost. A significant difference in CVRC between asymptomatic and symptomatic patients and a close correlation between CVRC and the existence of symptoms suggest that CVRC could be an early mark index to stage the risk of stroke and to guide further therapy. [50] The advantages of low cost, wide availability, and bedside operability make TCD an attractive technique for detecting acute ischemia or intracranial stenosis and sonothrombolysis. [51] managEmEnt of asymptomatic carotid stEnosis Current management for patients with ACS includes medical therapy for all patients and revascularization (CEA or CAS) reserved for select patients. Recent data suggested that the annual rate of stroke in medically treated patients with an ACS had fallen below 1%, [52] which is lower than the risk of endarterectomy or carotid stenting, making routine revascularization unjustifiable for ACS except in the few patients at high risk of ipsilateral stroke.
Carotid endarterectomy
Randomized controlled trials in the 1990s had established CEA as a beneficial approach for selected patients with ACS. According to the Veterans Affairs Cooperative Study Group trial in 1993, CEA reduced the overall incidence of ipsilateral neurologic events in male patients with ACS but did not have a significant influence on the combined incidence of stroke and death. [53] The Asymptomatic Carotid Atherosclerosis Study (ACAS) during 1987-1993 found that CEA decreased the aggregate risk for stroke or death over 5 years from 11% (with medical treatment only) to 5.1%. [54] The Asymptomatic Carotid Surgery Trial (ACST) during 1992-2003 also found out that immediate CEA had significant benefits compared with indefinite deferral of any CEA. [55] Perioperative complications including stroke and myocardial infarction limit the use of CEA. In the ACAS trial, candidates for surgery were required to have a perioperative complication rate of <3%. [56] Similarly, the ACST reported a 3.1% perioperative complication rate. [55] Therefore, CEA is not recommended for patients with ACS unless the risk of perioperative events (stroke and death) is <3%, otherwise, the benefit from surgery would be negated. [57, 58] 
Carotid artery stenting
In the prospective carotid revascularization endarterectomy versus stent trial (CREST) trial, the rate of poor outcome in patients ≥70 years of age was higher with CAS than with CEA, [59] but CAS with a device to capture and remove emboli is still an effective alternative to CEA in patients at average or high risk for surgical complications.
A recent 5-year follow-up to the Asymptomatic Carotid Trial I showed that there were no significant differences between the stenting group and endarterectomy group in the rate of stroke or death within 30 days after procedure (2.9% vs. 1.7%, P = 0.33) or cumulative 5-year rate of stroke-free survival (93.1% vs. 94.7%, P = 0.44). [60] This trial included severe ACS patients ≤79 years of age. The results were also supported by the 10-year follow-up from the CREST trial [61] where no significant difference was found in the rate of the primary composite end-point between the CAS group (11.8%, 95% CI) and CEA group (9.9%, 95% CI), in which 47.2% of the patients were with ACS.
Compared with CEA restoration of chemoreceptor function, CAS may not acquire the same autonomic function as CEA. [62] Specifically, the complication rate may be greater with unfavorable aortic arch or carotid bifurcation anatomic features for CAS, in addition to the hazards of advanced age. [63] Intensive medical therapy versus revascularization therapy Current advances in medical therapy have narrowed the gap between medical and surgical treatment of CAD for reducing cardiovascular risk, as evident by the 91% reduction in stroke and 87% reduction in myocardial infarction by intensive medical therapy alone. [64, 65] With the relative risk reduction for the outcome of perioperative death or any stroke over 5 years of 30% to 50% and the absolute risk reduction (ARR) of 4% to 5.9%, revascularization seems less attractive. [66] The early benefit of aggressive medical management in SAMMPRIS trial also lends support to the use of intensive medical treatment in high-risk patients with ACS and intracranial stenosis. [67] A Russian trial had shown that compared with medical therapy, CEA and medical treatment reduced the risk of death and cerebrovascular events in patients with 70% to 79% carotid stenosis; however, this study had a small sample and was a nonrandomized trial. [68] More studies such as the stent-protected angioplasty versus carotid endarterectomy (SPACE-2) trial are still in need to clearly define the best treatment strategy, i.e., the addition of CEA and CAS in the background of medical therapy or medical therapy alone in patients with ACS. [69] Currently, intensive medical treatment mainly consists of statin therapy, antiplatelet therapy, control of risk factors such as hypertension and diabetes, and lifestyle changes. [70] Statins reverse the progression of carotid plaques and significantly reduce the risk of stroke by 15.6% for each 10% reduction in low-density lipoprotein cholesterol and confers a definite 24% reduction in major vascular events and a 30% relative risk reduction of stroke over 20 years. [71] [72] [73] In addition, the IDEAL study showed that compared with usual-dose statins and high-dose statins reduced the risk of composite secondary end events and nonfatal acute myocardial infarction. [74] It is thus recommended in the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol that patients with a high 10-year risk for cardiovascular events should receive a high dose of statin. [75] Nonstatin lipid-lowering drugs such as fibrates, ezetimibe, and newly approved proprotein convertase subtilisin/kexin type 9 (PCSK9) may also be considered in patients intolerable to statins or with familial hypercholesterolemia, though their value has not been firmly established.
Antiplatelet therapy can reduce the incidence of the combined outcome of any serious vascular event including nonfatal myocardial infarction, stroke, and death by 25% among high-risk patients. [76] Aspirin, P2Y12 inhibitor, or cilostazol is protective in patients at increased risk of occlusive vascular events derived from ACS. Although there was limited evidence of efficacy, aspirin was recommended in the 2014 AHA/ASA Guidelines for the primary prevention of stroke in ACS patients. [77] Dual-antiplatelet therapy (DAPT) in the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial showed early benefits of DAPT therapy in minor ischemic stroke or TIA by reducing the risk of subsequent stroke to 32% without increasing hemorrhage. [78] However, dual-antiplatelet therapy may not benefit all patients with acute stroke or with ACS, unless the patient has concomitant symptomatic coronary artery disease, severe peripheral artery disease, or recent coronary stenting. [76, [79] [80] [81] Hypertension is the most important modifiable risk factor for preventing stroke. Control of hypertension has been shown to reduce the incidence of stroke by 30% to 40%. [82] Optimal blood pressure (BP) targets remain unclear as most guidelines generally recommend a systolic BP of <140 mmHg and diastolic BP of <90 mmHg. For individuals with an older age, a more stringent goal would be beneficial in reducing major cardiovascular events, including stroke. [83, 84] However, in patients with severe carotid stenosis, cautious measures should be taken to avoid aggressive reductions in BP due to the possibility of insufficient brain perfusion. Although reduction of BP is presumed to be more important than the choice of a specific drug, some studies have suggested that angiotensin-converting enzyme inhibitors offer more benefits than beta-blockers for the same drop in BP, possibly due to their other physiological effects. [81, 82] Last but not least, lifestyle modifications consisting of smoking cessation, limited alcohol consumption, weight control, regular aerobic exercise, and a healthy diet should be encouraged in patients with ACS. Smoking increases the overall risk of stroke by 150%, making its cessation mandatory. [85] Light alcohol consumption may decrease the risk of cardiovascular events while heavy alcohol consumption has been linked to a higher risk. [86] The Mediterranean diet supplemented with extra-virgin olive oil or nuts is recommended for people at high risk of cardiovascular events as it contains a broad combination of antioxidants. [87, 88] 
Suggest approach to asymptomatic carotid stenosis
For patients with ACS, intensive medical treatment alone may be effective enough and revascularization should be reserved for selected patients whose life expectancy is ≥5 years, stenosis at baseline or progression is >80%, and perioperative risks including stroke and death is <3%. As for patients at high risk of revascularization or <5 years life expectancy, intensive medical treatment alone may be more suitable. [89] In choosing revascularization strategies, CAS is preferred in patients who have become recently symptomatic (<2 weeks), are older than 75 years of age, have a tortuous or heavily calcified aortas, and have long or heavily calcified lesions, while CEA is more suitable in those with contralateral carotid occlusions, recurrent carotid stenosis, and significant cardiac and lung diseases. [63] managEmEnt of symptomatic carotid stEnosis
The optimal treatment of SCS is less controversial for symptomatic patients than asymptomatic patients and revascularization is still supported and favored over medical therapy alone for moderate-to-severe symptomatic patients. [89] Carotid endarterectomy CEA was developed in 1954 as a surgical option for stroke prevention in patients with SCS and its prophylactic application rose dramatically even without strong evidence of benefits until the mid-1980s. Following this, randomized controlled trials throughout the United States, Canada, and Europe established CEA as safe and effective for reducing the risk of ischemic stroke in patients with SCS. [5, 27, 90] For symptomatic patients with severe carotid stenosis, the NASCET trial [26] showed an absolute reduction of 17% in the risk of ipsilateral stroke at 2 years (P < 0.001), with perioperative morbidity and mortality quite acceptable at a rate of 2.1% for major stroke and 0.6% for death. In the 3-year follow-up of the ECST trial, [90] risk of ipsilateral stroke was 2.8% in CEA-treated patients compared with 16.8% in medically treated patients. Patients with moderate SCS benefited less from CEA, with the risks of any ipsilateral ischemic stroke of 15.7% with CEA and 22.2% with medical therapy (P = 0.045) in 5-year follow-up. [91] A synthesis of randomized controlled trials concluded that CEA is highly beneficial for patients with 70% to 99% stenosis and of marginal benefit for patients with 50% to 69% symptomatic stenosis, while no benefit was observed in patients with <50% stenosis. [92] Carotid artery stenting Carotid angioplasty and stenting is a more recent revascularization procedure utilized to treat patients at high surgical risk for CEA. The SPACE endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) and CREST trials generally found that CAS and CEA had the similar rates of perioperative events. [93] [94] [95] CAS, however, is associated with a higher procedural risk of stroke and lower risk of myocardial infarction than CEA in patients with SCS. [96] A 7-year follow-up of EVA-3S study showed both techniques were associated with low and similar long-term risks of recurrent ipsilateral stroke beyond the procedural period, while CEA did have a lower risk of stroke during the procedural period. [97] Long-term results of CREST reported no significant differences between CAS and CEA in the risk of perioperative stroke, myocardial infarction, or postoperative ipsilateral stroke in 10 years. [61] It is important to note that age has a huge impact on perioperative risk when choosing between CEA or CAS. The CAS versus CEA perioperative hazard ratio was determined to be 1.61 (95% CI: 0.90-2.88) for patients aged 65-69 years and 2.09 (95% CI: 1.32-3.32) for patients aged 70-74 years. [98] It is in agreement with current recommendations that CEA should be preferred over CAS in patients older than 70 years.
In conclusion, CEA remains the standard revascularization option for patients of severe SCS (>70% stenosis) with perioperative stroke and death rate lower than 6%, while CAS may be better for patients with certain high-risk feature, including high cervical lesions above C2, previous cervical irradiation, or post-CEA restenosis. The value of CAS as an equivalent alternative to CEA is still questionable, calling for more trials in the future. At present, the application of CAS should be selective and must be done by experienced operators at experienced centers. [99] 
Timing of revascularization
The timing of revascularization in patients with SCS remains controversial. Post hoc analysis from NASCET and ECST trials suggest that the greatest benefit is obtained when performing CEA within 2 weeks after a stroke event, with an ARR in perioperative stroke of 30.2%. ARR fell to 18% and 11% when delaying surgery to 2-4 weeks and 4-12 weeks, respectively. [100] The decline in benefit of CEA over time was more rapid in women than in men. [101] On the other hand, pooled data suggested revascularization performed within the first 48 h of a carotid stroke had a higher risk of perioperative stroke, especially in those with stroke as index event (8.0%; 95% CI: 4.6% to 12.5%). [102] Hyperperfusion following CEA may be responsible as it induces reperfusion injury and increases the risk of intracerebral hemorrhage and thrombus translocation. [103] A recent summary and meta-analysis on early carotid intervention showed similar risks in perioperative stroke when revascularization is performed within 15 or 7 days after an index event for CEA (3.4% vs. 3.3%, within 15 days and 7 days, respectively) or CAS (4.6% vs. 4.6, within 15 days and 7 days, respectively). It suggested that carotid revascularization can be safely performed earlier (0-7 days) than current recommendations. [102] Currently, there is an ongoing randomized controlled trial examining the timing of cerebral revascularization, and its results may have further implications in the future. [104] Suggested approach to symptomatic carotid stenosis
Optimal treatment strategies for SCS should be based upon intensive medical therapy as it is for ACS and should balance the risk and benefit from both revascularization approaches. [77, [105] [106] [107] For patients with <50% stenosis, medical therapy should be implemented with no need of CEA and CAS. For patients with SCS and severe stenosis of 70%-99%, CEA is recommended when the perioperative events (stroke/death) rate is <6%. CEA should be consider in patients with stenosis of 50%-69%. CAS is indicated as an alternative when its perioperative events rate is <6% and should be favored in patients with severe cardiac disease, history of irradiation, stenosis distal to the second cervical vertebra, and previous ipsilateral CEA. In addition, patient age should be take into consideration when choosing between CEA and CAS. Once decided, revascularization should be perform within 2 weeks but not in the first 48 h after stroke or TIA.
summary
Patients with CAD remain at high risk for adverse cardiovascular events, especially stroke and myocardial infarction. Significant development and standardized implementation of recent medical therapy have dramatically driven down the rates of stroke among patients with ACS. However, more studies are still required to better stratify patients with high-risk profiles that would benefit from more invasive therapies. Also unclear is the decision on which revascularization method a patient should receive. More advanced devices and techniques are being developed to further overcome the procedural complications in patients undergoing endarterectomy or carotid artery stenting. We are looking forward to more clinical trials to amend the current treatment standards for a better management of CAD.
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